You are here


March 18, 2016
MHRP and Collaborators Presenting at Keystone Symposia HIV Vaccine and HIV Persistence Meetings

MHRP and collaborators are scheduled to speak and present at the 2016 Keystone Symposia HIV Vaccine and HIV Persistence meetings taking place March 20-24 in Olympic Valley, California.

Dr. Merlin Robb, MHRP’s clinical deputy director, is scheduled to speak during a plenary session focusing on immunologic correlates on March 21. Using examples gleaned from follow-up studies to MHRP’s...

March 16, 2016
Study Compares Hospitalization Rates Among HIV Controllers and Those With Medically Controlled HIV in Military Cohort

A new study published this week in the Journal of the International AIDS Society investigated hospitalization rates and reasons in the U.S. Military HIV Natural History Study (NHS), comparing patients with spontaneous virologic control of HIV to patients with medically controlled HIV.

“HIV controllers (HICs) maintain an undetectable viral load and high CD4 counts without antiretroviral...

March 8, 2016
Biomarkers of Disease Progression Appear to Differ in Sub-Saharan Population

Immune activation and inflammation help predict HIV disease progression and AIDS mortality in industrialized countries. These associations are different for a Sub-Saharan African population, according to an article published this week in the Journal of Acquired Immune Deficiency Syndromes.

The study assessed biomarkers of inflammation, microbial translocation, and cellular activation in...

February 22, 2016
MHRP Scientists and Collaborators Presenting at CROI 2016

MHRP and collaborators will give the following poster presentations at the annual Conference on Retroviruses and Opportunistic Infections (CROI) taking place February 22-25 in Boston: 

Tuesday, February 23 Western Blot Index for Estimating Recency of HIV Infection​  –Mark Manak (MHRP) Poster 515, Session P-M1, 2:45 p.m., Exhibit Hall A/B​

Virologic Failure is Uncommon After...

February 16, 2016
First-in-Human Phase 1 Clinical Trial of MERS Vaccine Begins

The Walter Reed Army Institute of Research (WRAIR) began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).

Though other vaccine candidates have previously been tested for use in camels, which are the suspected source of the coronavirus which causes MERS (MERS-CoV), this...

January 6, 2016
MHRP, WRAIR Begin New Phase 2 Clinical Trial of Ebola Vaccine Regimens

The Walter Reed Army Institute of Research (WRAIR) today announced the initiation of a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime-boost Ebola vaccine regimen in both healthy and HIV-infected study volunteers.

This study includes two vaccine candidates, Ad26.ZEBOV from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson &...

January 5, 2016
MHRP Scientist Discusses WHO Ebola Collaboration

As an Ebola outbreak surged across West Africa in 2014, MHRP research physician, Dr. Kayvon Modjarrad, sought a way to aid response efforts. His opportunity to fight the epidemic came via Geneva, Switzerland, where he was requested by name to help the World Health Organization oversee Phase I trials for an Ebola vaccine candidate.

While in Geneva, Dr. Modjarrad was charged with guiding...

November 30, 2015
World AIDS Day 2015: The Time to Act is Now

The U.S. Military HIV Research Program (MHRP)/Walter Reed Army Institute of Research (WRAIR) seeks to protect U.S. troops and reduce the global impact of HIV through a combined focus on developing a globally effective HIV vaccine and finding a cure.

The landmark RV144 Thai vaccine study, the only vaccine clinical trial to show a modest ability to protect against HIV infection,...

November 30, 2015
Prospects for a Globally Effective HIV-1 Vaccine

A commentary in the December issues of American Journal of Preventive Medicine and Vaccine make the case for the development of a globally cost-effective HIV-1 vaccine that would protect against the many HIV-1 strains and varied routes of transmission.

The authors, including MHRP deputy director Dr. Merlin Robb, reviewed different HIV-1 vaccine approaches currently being pursued and the...

October 21, 2015
New Study Highlights Need for Hepatitis C Screening for U.S. Military Applicants

A new study shows that two-level screening of military applicants for hepatitis C (HCV)—via antibody screening and a confirmatory nucleic acid test—could not only reduce enlistment of infected individuals and increase battlefield blood safety, but also save the DoD an estimated $3.1 million annually. The study was published online today in the journal Hepatology.

Battlefield whole blood...